Smart science to improve lives™
Banner image for japan country page

Japan

Croda Japan was originally formed as a 50:50 partnership of Croda International in 1966, and in 1989 became wholly owned by Croda. One of the pioneering foreign-owned companies to establish its own manufacturing site in Japan, our site in Shiga also developed a process that produces products of extremely high levels of purity, primarily for Personal Care and Health Care. In 2013, it was the second manufacturing site in Japan to be awarded the EFfCI (European Federation for Cosmetic Ingredients) GMP certification and in 2017 was the first in Japan to be awarded the EXCIPACT certificate. Producing a wide range of natural-based specialties from materials such as vegetable oils and lanolins, we also manufacture esters and wax.

The working environment is a good balance of Japanese culture with the dynamism of a global company. Our team enjoys the Croda culture of “safety first, people first”, with employee wellbeing a priority. 


Croda Japan KK

Shinjuku Park Tower 11th Floor
3-7-1, Nishi-shinjuku, Shinjuku-ku
Tokyo, Japan 163-1011
Tel: +81(0) 3 6258-1910
Fax: +81(0) 3 5322-2122


Shiga Manufacturing Site

Gokasho Hiyoshi-cho
Higashiomi-shi
Shiga, Japan, 529-1403
Tel: +81 (0)748 48 3701
Fax: +81 (0)748 45 5721 

Further reading

Sustainability expert Aris Vrettos joins Croda

The new position will see the sustainability expert challenge Croda to stretch its already industry-leading sustainability ambitions and commitments and support Croda’s business sectors in further...

Completed divestment – transitioning to a pure-play Consumer Care and Life Sciences company

Accelerating our transition to a pure-play Consumer Care and Life Sciences company, completion of the divestment of the majority of our Performance Technologies and Industrial Chemicals businesses to...
Laboratory work

UK Government to support expansion of Croda's lipid systems manufacturing facility

31 March 2022: This investment will significantly enhance the development of high-purity lipid systems, essential delivery systems for next generation nucleic acid drugs such as mRNA vaccines.

U.S. Government to support expansion of Croda lipid systems capability

Today we announce a joint investment with the U.S. government to expand our U.S manufacturing capacity for lipid systems used in novel therapeutic drugs, such as mRNA vaccines